Clinical trials News Fulcrum Therapeutics® Announces Phase 3 Clinical Trial of Losmapimo (REACH) March 3, 2022 By Bine Haase https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeuticsr-announces-reach-phase-3-clinical-trial/?fbclid=IwAR2WpAYsthlB2it094PMDEGP9b671YY5pKh7vQSgU10IEc5vxzHqMIu5rj4 Post navigation Previous PostPrevious FSHD European Trial Network (FSHD ETN) Newsletter 2 – January 2022Next PostNext Update and News regarding the Patient Pharma Survey!